Biogen Submits Biologics License Application to FDA for First Long-Lasting Factor IX Therapy for Hemophilia B

Biogen Submits Biologics License Application to FDA for First Long-Lasting Factor IX Therapy for Hemophilia B

By: Latest Articles from Benzinga.com

Posted on January 04, 2013 at 07:34 AM EST

Today Biogen Idec (NASDAQ: BIIB ) announced the company recently submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval

Related Stocks:

Biogen Idec, Inc. NewStar Financial, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates